ReviewDrugs2023
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 30 citations in OpenAlex.
- Baicalin ameliorates podocyte injury and renal function impairment in idiopathic membranous nephropathy by inhibiting the AGE/RAGE signaling.Renal failure · 2026Article
- Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.International urology and nephrology · 2026Article
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy.BMC nephrology · 2026Article
- Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study.BMC nephrology · 2026Observational
- Systematic prioritization of potential therapeutic targets for glomerulonephritis using multi-omics Mendelian randomization.PLoS computational biology · 2026Article
- Obinutuzumab Versus Rituximab for the Treatment of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system.Clinics (Sao Paulo, Brazil) · 2026Article
- Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?Drug design, development and therapy · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Treatment options for patients with high anti-PLA2R antibodies in primary membranous nephropathy: a single-center cohort retrospective study.BMC nephrology · 2025Article
- Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review.Journal of clinical medicine · 2025Review
- Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.Kidney international reports · 2025Article
- Clinical evaluation of strengthening spleen and draining dampness in the treatment of idiopathic membranous nephropathy: a retrospective 10-year follow-up study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy.BMC pharmacology & toxicology · 2025Article
- The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2025Review
- Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy.Frontiers in immunology · 2025Article
- Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
When first introduced, rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, brought about an alternative therapeutic paradigm for primary membranous nephropathy (PMN). Rituximab was shown to be effective and safe in PMN patients with kidney dysfunction, with. patients receiving second-line rituximab therapy achieving remission as effectively as those patients who had not previously received immunotherapy. No safety issues were reported. The B cell-driven protocol seems to be as efficient as the 375 mg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.